Open Access

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate

  • Authors:
    • Yongjian Zhou
    • Jiabi Chen
    • Xiaoyuan Weng
    • Guosheng Lin
    • Zicheng Huang
    • Hanli Shui
  • View Affiliations

  • Published online on: March 16, 2018     https://doi.org/10.3892/ol.2018.8283
  • Pages: 7589-7594
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, imatinib mesylate (IM) was used to induce resistance in the gastrointestinal stromal tumour (GIST) cell line, GIST‑T1, to establish a stable resistant cell line. The growth characteristics and expression profile of the established cell line were compared with those of the parental cell line. Additionally, the resistance mechanism of the gastrointestinal stromal tumours was preliminarily investigated. The GIST‑T1 cells were cultured in vitro, and the drug was administered in the logarithmic phase of cell growth using intermittent dosing with increasing concentrations to obtain a drug‑resistant cell line by repeated induction. Differences in the biological behaviours of the parental cells and drug‑resistant cells were examined, and changes in the expression profiles were compared in the two cell lines. The results showed that the IM‑resistant GIST‑T1 cell line (GIST‑T1 IR) was successfully established. Analysis of the biological behaviours of the two cell lines revealed that the average doubling times of the parental cells and drug‑resistant cells were 26.59 and 33.63 h, respectively. The results of a scratch migration assay revealed that the migration ability was enhanced in the GIST‑T1 IR cells. The results of CCK‑8 detection indicated that the half maximal inhibitory concentration values of the two types of cells were 10.5 and 42.0 µM, respectively, which represented an increase of ~4‑fold in the GIST‑T1 IR cells. Flow cytometric cell cycle analysis indicated that the numbers of cells in the G0/G1, S and G2 phases increased following the induction treatment. Taken together, an IM-resistant GIST T1 cell line was successfully established, which opens novel avenues for individualized tumour chemotherapy.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou Y, Chen J, Weng X, Lin G, Huang Z and Shui H: Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate. Oncol Lett 15: 7589-7594, 2018
APA
Zhou, Y., Chen, J., Weng, X., Lin, G., Huang, Z., & Shui, H. (2018). Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate. Oncology Letters, 15, 7589-7594. https://doi.org/10.3892/ol.2018.8283
MLA
Zhou, Y., Chen, J., Weng, X., Lin, G., Huang, Z., Shui, H."Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate". Oncology Letters 15.5 (2018): 7589-7594.
Chicago
Zhou, Y., Chen, J., Weng, X., Lin, G., Huang, Z., Shui, H."Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate". Oncology Letters 15, no. 5 (2018): 7589-7594. https://doi.org/10.3892/ol.2018.8283